ClinicalTrials.gg

Program

nacresertib

Also written as “Nacresertib”.

Its studies are led by AbbVie.

Furthest: phase 1, since Apr 29, 20263 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie30 open or runningphase 1since Apr 29, 2026Apr 29, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2026First study: phase 1 study in Healthy VolunteersFirst studyNCT07566130 · 93 enrolled · United States
  2. May 14, 2026Phase 1 study in Healthy VolunteerNCT07600762 · 12 enrolled · United States
  3. Jun 11, 2026Phase 1 study in Healthy VolunteerNCT07649954 · 12 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07649954Healthy Volunteer · United States1CompletedOct 5, 202612
NCT07600762Healthy Volunteer · United States1CompletedJun 17, 202612
NCT07566130Healthy Volunteers · United States1CompletedMay 7, 202693

How it is read

Names in the registry

  • “Nacresertib”, 2 entries
  • “nacresertib”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.